Hua Medicine put Bayer AG in charge of China commercialization of its lead program -- dorzagliatin, a novel treatment for type 2 diabetes. Hua will receive $58 million upfront and up to $600 million in milestones. In China, Bayer is a major player in the diabetes market because of Glucobay®, its generic oral treatment for type 2 diabetes. Hua Medicine will continue to be responsible for clinical development, registration, product supply and distribution, while Bayer will take over marketing, promotion and medical education. More details.... Stock Symbols: (HK: 2552) (Xetra: BAYN) Share this with colleagues: // //